Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
NCT04051606Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jul 2019
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in glioblastoma (GBM), sponsored by Case Comprehensive Cancer Center. Started Jul 2019; status: completed.
02
Drugs
regorafenib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04051606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04051606.